Beauty

Shiseido to Sell China's Aupres Owner SLC to IDG-Led Consortium

The Japanese cosmetics group is divesting its Chinese subsidiary as part of a 2030 strategy focused on profitability and capital efficiency, while arranging IP licensing and transitional support.

Ingrid LindqvistNovember 19, 20265 min read2 views
A conceptual editorial scene showing generic skincare containers and a production line being divided into separate pathways, suggesting a corporate divestment and managed transition.

Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-headquartered private equity firm IDG Capital. SLC makes and sells the Aupres brand in China.

The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Financial terms were not disclosed.

Divestment tied to 2030 strategy

Shiseido framed the sale as part of its effort to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. The group said it aims to drive sustainable growth and strengthen its competitiveness in China by concentrating management resources on areas where it enjoys the greatest competitive advantage.

According to Shiseido, the sale removes a business that requires continued investment in product innovation and digital capabilities. The divestment is intended to allow the group to focus on priority brands and higher-growth opportunities.

Shiseido described China as a strategically important and attractive, dynamic market where the competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants.

SLC ownership and transition terms

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group owned by the Beijing Municipal Government. It has sold the C-beauty brand Aupres since 1994.

With the current joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan's 35% stake, giving it full ownership ahead of the sale.

Under the transaction, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles. A limited partnership enterprise set up mainly by SLC's new management team will hold the remaining 5%.

The deal includes SLC's Beijing factory and production equipment. Shiseido said it believes independent operation under IDG will support SLC's sustainable growth and brand value.

To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The remaining collaboration is intended to maintain SLC's innovation capabilities, product quality and business continuity.

Profit recovery precedes sale

The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion, or US$422.13 million. The recovery was attributed to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%.

Shiseido raised its full-year core operating profit forecast from ¥59 billion, or US$433 million, to ¥87 billion, or US$546 million, on the back of those results.